Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
Provided By GlobeNewswire
Last update: Oct 6, 2025
Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission
Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting
Read more at globenewswire.com
